PE20090112A1 - Derivados de indol como agonistas del receptor de canabinoides cb1 - Google Patents

Derivados de indol como agonistas del receptor de canabinoides cb1

Info

Publication number
PE20090112A1
PE20090112A1 PE2008000362A PE2008000362A PE20090112A1 PE 20090112 A1 PE20090112 A1 PE 20090112A1 PE 2008000362 A PE2008000362 A PE 2008000362A PE 2008000362 A PE2008000362 A PE 2008000362A PE 20090112 A1 PE20090112 A1 PE 20090112A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
tiadiazol
tetrahydropyran
chloro
Prior art date
Application number
PE2008000362A
Other languages
English (en)
Inventor
Julia Adam
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20090112A1 publication Critical patent/PE20090112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN DERIVADO DE INDOL DE FORMULA (I), DONDE A ES UN ANILLO HETEROCICLICO AROMATICO DE 5 MIEMBROS; X1, X2 Y X3 SON N, O, S O CH; Y ES CH2, O, S, SO2; R1 ES H, ALQUILO C1-C4, ALQUILOXI C1-C4, CN O HALOGENO; R2, R2', R3, R3', R4, R4', R5 Y R5' SON H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON OH, CO-OR8, ENTRE OTROS; n ES 1 O 2; R6 ES H, ALQUILO C1-C4, CO-NR9R10, CO-OR11, ENTRE OTROS; R7 ES H O HALOGENO; R8 ES ALQUILO C1-C4; R9 Y R10 SON H, ALQUILO C1-C4, CICLOALQUILO C3-C7, ENTRE OTROS; R11 ES H O ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 3-({5-4-(CARBAMOILMETIL)-PIPERAZIN-1-IL]METIL}-[1,2,4]-TIADIAZOL-3-IL)-7-CLORO-1-(TETRAHIDROPIRAN-4-IL)METIL-1H-INDOL, 7-CLORO-3-({5-[4-(ETILCARBAMOILMETIL)PIPERAZIN-1-IL]METIL}-[1,2,4]-TIADIAZOL-3-IL)-1-(TETRAHIDROPIRAN-4-IL)METIL-1H-INDOL, 7-CLORO-3-({5-[4-(SULFAMOILPIPERAZIN-1-IL]METIL}-[1,2,4]-TIADIAZOL-3-IL)-1-(TETRAHIDROPIRAN-4-IL)METIL-1H-INDOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR DE CANABINOIDES CB1 Y SON UTILES EN EL TRATAMIENTO DEL DOLOR CRONICO, DOLOR NEUROPATICO, DOLOR PERIOPERATORIO, ENTRE OTROS
PE2008000362A 2007-02-22 2008-02-20 Derivados de indol como agonistas del receptor de canabinoides cb1 PE20090112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07102870 2007-02-22

Publications (1)

Publication Number Publication Date
PE20090112A1 true PE20090112A1 (es) 2009-02-26

Family

ID=38283196

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000362A PE20090112A1 (es) 2007-02-22 2008-02-20 Derivados de indol como agonistas del receptor de canabinoides cb1

Country Status (18)

Country Link
US (1) US7655645B2 (es)
EP (1) EP2125795B1 (es)
JP (1) JP5324476B2 (es)
KR (1) KR20090113383A (es)
CN (1) CN101616914B (es)
AR (1) AR065393A1 (es)
AU (1) AU2008219226B2 (es)
BR (1) BRPI0807867A2 (es)
CA (1) CA2678147A1 (es)
CL (1) CL2008000514A1 (es)
EC (1) ECSP099593A (es)
IL (1) IL199848A0 (es)
MX (1) MX2009008316A (es)
PE (1) PE20090112A1 (es)
RU (1) RU2009135255A (es)
TW (1) TW200848417A (es)
WO (1) WO2008101995A1 (es)
ZA (1) ZA200905265B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
US7763732B2 (en) * 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives
UY32147A (es) * 2008-09-29 2010-04-30 Abbott Lab Derivados de indol y de indolina y métodos para usarlos
EP2632257B1 (en) 2010-10-25 2021-03-31 Vanderbilt University Compositions for inhibition of insect host sensing
WO2012154403A2 (en) 2011-05-06 2012-11-15 Vanderbilt University Composition for inhibition of insect sensing
CN102757427A (zh) * 2012-07-09 2012-10-31 陕西科技大学 2-氨基-5-异二氢吲哚-1,3-二酮甲基1,3,4-噻二唑及其制备方法
BR112017020440A2 (pt) 2015-03-25 2018-07-03 Univ Vanderbilt métodos de interromper o comportamento de percepção de odor em um organismo com um canal de íon de orco e de agonização de um canal de íon de orco, composição para interromper a percepção de odor, e, artigo.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939138A (en) * 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
EP1363632B1 (en) 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
CA2549147C (en) 2003-12-17 2012-04-10 Akzo Nobel N.V. Tricyclic 1-((3-indol-3-yl)carbonyl) piperazine derivatives as cannabinoid cb1 receptor agonists
TWI330635B (en) * 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
EP1904068A1 (en) * 2005-07-11 2008-04-02 N.V. Organon Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
TW200745096A (en) 2005-08-23 2007-12-16 Organon Nv Indole derivatives
US7763732B2 (en) * 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives

Also Published As

Publication number Publication date
JP5324476B2 (ja) 2013-10-23
MX2009008316A (es) 2009-08-12
AR065393A1 (es) 2009-06-03
AU2008219226A1 (en) 2008-08-28
CA2678147A1 (en) 2008-08-28
JP2010519278A (ja) 2010-06-03
ECSP099593A (es) 2009-09-29
TW200848417A (en) 2008-12-16
ZA200905265B (en) 2010-04-28
KR20090113383A (ko) 2009-10-30
IL199848A0 (en) 2010-04-15
WO2008101995A1 (en) 2008-08-28
CL2008000514A1 (es) 2008-06-20
RU2009135255A (ru) 2011-03-27
BRPI0807867A2 (pt) 2014-06-03
EP2125795B1 (en) 2013-03-20
CN101616914B (zh) 2012-10-10
EP2125795A1 (en) 2009-12-02
CN101616914A (zh) 2009-12-30
US7655645B2 (en) 2010-02-02
US20080207598A1 (en) 2008-08-28
AU2008219226B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
PE20090112A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20080997A1 (es) Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20110574A1 (es) Derivados de fenilamida y de piridilamida como agonistas de gpbar1
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20090592A1 (es) Nuevos derivados de piperazina-amida
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20081559A1 (es) DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
MY146494A (en) Indole sulfonamide modulators of progesterone receptors
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
PE20081378A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
PE20060572A1 (es) Compuestos de benzoimidazolona como inhibidores de hsp90
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors

Legal Events

Date Code Title Description
FC Refusal